ChemoMetec's Guidance for the Upcoming Financial Year
ChemoMetec has recently announced its financial guidance for the 2025/26 financial year, a significant development for stakeholders and investors alike.
Projected Revenue and EBITDA
In the forthcoming financial year, ChemoMetec anticipates revenues reaching between DKK 545 million and DKK 565 million. This marks a noticeable increase from the previous financial year's revenue of DKK 495.6 million. Moreover, the company expects its EBITDA to be in the range of DKK 295 million to DKK 315 million, compared to DKK 258 million the prior year.
Understanding the Guidance Parameters
The guidance provided by ChemoMetec is based on detailed assumptions and insights outlined in its annual report for 2024/25. This report serves not only to present financial results but also to clarify the rationale and projections for the future. Investors and analysts can gain a better understanding of the factors influencing these expectations by reviewing the relevant pages in the report.
Company Overview and Market Position
Founded in 1997, ChemoMetec A/S has carved a niche in developing and manufacturing state-of-the-art instruments designed for cell counting and various measurements. The company has established a robust presence in multiple sectors, including pharmaceuticals, biotech, and agriculture, catering to some of the leading pharmaceutical giants globally.
Leadership and Contact Information
The leadership at ChemoMetec plays a pivotal role in guiding the company through its financial and operational strategies. Martin Helbo Behrens serves as the CEO, while Kim Nicolajsen holds the position of CFO. For inquiries, stakeholders can reach them at (+45) 48 13 10 20.
Commitment to Innovation and Quality
ChemoMetec places a strong emphasis on quality and innovation, continuously striving to enhance its product offerings. The company’s commitment to research and development ensures that it stays at the forefront of technological advancements within its industry.
Frequently Asked Questions
What is ChemoMetec's expected revenue for the 2025/26 financial year?
ChemoMetec expects its revenue to be between DKK 545 million and DKK 565 million for the financial year 2025/26.
How does the projected EBITDA compare to the previous year?
The projected EBITDA for 2025/26 ranges from DKK 295 million to DKK 315 million, which is an increase from DKK 258 million in 2024/25.
Where can I find more information about ChemoMetec?
For more information, you can visit ChemoMetec's official website at www.chemometec.com.
Who are the key figures in ChemoMetec's leadership?
The key figures in ChemoMetec's leadership are Martin Helbo Behrens, the CEO, and Kim Nicolajsen, the CFO.
In which industries does ChemoMetec operate?
ChemoMetec operates in the pharmaceutical, biotech, and agricultural industries, providing advanced instruments for cell counting and other measurements.
